Receptor News and Research

RSS

Could the gut be priming the body for a more severe stroke?

Gut bacteria may prime immune cells to worsen stroke damage

2 Oct 2026

COVID-19 immunity shows cross-reactivity against related bat coronaviruses

People who recovered from COVID-19 infection or were vaccinated against SARS-CoV-2 are more likely to have immunity to other closely related bat coronaviruses that could have the potential to threaten future human health.

1 Oct 2026

Postpartum GLP-1 prescriptions rise sharply among U.S. women

More U.S. women are being prescribed GLP-1 medications after giving birth, particularly those diagnosed with diabetes, according to new research from the USC Schaeffer Center for Health Policy & Economics.

1 Oct 2026

New study reveals how VEGF-C amplifies lymphangiogenic signaling

Lymphatic vessels act as the body's "drainage system," collecting excess fluid from tissues. When lymphatic drainage is impaired because lymphatic vessels are underdeveloped, damaged, or dysfunctional, lymphedema can develop, causing swelling, particularly in the arms and legs.

1 Oct 2026

CBL-514 injection reduces visceral and subcutaneous fat in trials

Details of a new injection that targets fat cells will be released at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2).

1 Oct 2026

Synthetic protein targets TLR4 membrane region to reduce inflammation

To sense their environment and respond accordingly, cells enlist membrane proteins as communication hubs, receiving molecular messages from outside and triggering responses inside.

1 Oct 2026

Spatial mapping reveals macrophage niches linked to severe COVID-19 lung injury

Researchers at the University of Liège have used imaging-based spatial single-cell transcriptomics to map the cellular organization of lungs from people who died with severe COVID-19.

1 Oct 2026

Gut bacterial metabolite worsens brain damage after stroke, study finds

Researchers at LMU have discovered how a metabolite produced by gut bacteria can influence brain damage after stroke.

1 Oct 2026

Trevogrumab cuts semaglutide-induced lean mass loss by half, study shows

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and in press with The Lancet shows that using the trevogrumab to inhibit myostatin, a protein that negatively regulates muscle mass, can reduce lean mass loss during treatment with semaglutide by 50% compared with semaglutide and placebo.

1 Oct 2026

Esophageal cancer leaves a distinct metabolic signature in the gut

The study uncovers gut microbial and metabolic signatures in esophageal cancer, emphasizing lipid dysregulation and its potential role in disease progression.

1 Oct 2026

Real-world data reveals higher reported GLP-1 side effects in female patients

The second of a Series of papers presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health discusses the wide-ranging issues relating to use of GLP-1 RA drug use in women.

1 Oct 2026

GLP-1 receptor agonist exposure shows no link to major adverse pregnancy outcomes

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Obstetrics, Gynaecology & Women's Health shows that, following a review and meta-analysis of available studies, use of glucagon-like peptide-1 receptor agonists (GLP-1 RA) drugs for diabetes and weight management in women living with diabetes is not associated with adverse pregnancy outcomes in most cases.

1 Oct 2026

Study examines the real-world use of GLP-1 RA drugs in children and young people

New research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) has examined the real-world use of GLP-1 receptor agonist (GLP-1 RA) drugs in children and young people in Germany, Austria and Luxembourg.

30 Sep 2026

Nuclear enzyme discovery unlocks new paths to combat breast cancer

One of the major challenges in the treatment of the most common subtype of breast cancer (hormone receptor positive, HR+) is the emergence of resistance.

30 Sep 2026

Overall dietary patterns matter more for heart health than nutrients

A healthy, balanced dietary pattern, rather than one focused on individual nutrients or foods is key to maintaining heart health, according to a Scientific Statement issued by the American College of Cardiology and published in JACC, its flagship journal.

30 Sep 2026

Petrelintide produces double-digit weight loss with fewer side effects

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) and published in The Lancet Diabetes & Endocrinology shows that weekly injections with the new amylin-based obesity drug petrelintide can enable those treated to lose more than 10% of their body weight – generally lower than existing incretin-based (GLP-1 RA) drugs, but also with far fewer side effects.

29 Sep 2026

Intestinal enzyme links microbial metabolism to MASH progression

Metabolic dysfunction-associated steatohepatitis (MASH) is often viewed through the lens of hepatic lipid accumulation, inflammation and fibrosis. A new study published in eGastroenterology shifts attention upstream, identifying intestinal neutral ceramidase as a gut-derived driver of MASH progression through its effects on microbial metabolism, epithelial signalling and intestinal barrier function.

29 Sep 2026

Targeting specific nuclear receptor could help preserve aging muscle function

Scientists in the Gerhart-Hines Group pinpoint a molecular cause of muscle aging, and a possible fix. By investigating how muscles adapt to age and disease-related decline, the scientists discovered the involvement of a druggable nuclear receptor, ERRγ, that could be targeted to preserve muscle function.

29 Sep 2026

New registry data shows semaglutide does not cause pancreatic cancer

New research to be presented at the Annual Meeting of The European Association for the Study of Diabetes (EASD) in Milan, Italy (Sept 28 – Oct 2) shows no link between semaglutide use and pancreatic cancer using nationwide registry data from Denmark, Sweden and Norway.

29 Sep 2026

Can’t stop thinking about food? You’re far from alone

Investigating 'food noise', this study reveals its association with diet quality and mental health, emphasizing demographic influences and eating behaviors.

29 Sep 2026